

## Supplementary Materials for

### Rapid and specific detection of Asian- and African-lineage Zika viruses

**Authors:** Nunya Chotiwan<sup>1,2†</sup>, Connie D. Brewster<sup>1†</sup>, Tereza Magalhaes<sup>2,8</sup>, James Weger-Lucarelli<sup>1,2</sup>, Nisha K. Duggal<sup>3</sup>, Claudia Rückert<sup>1,2</sup>, Chilingh Nguyen<sup>1,2</sup>, Selene M. Garcia Luna<sup>1,2</sup>, Joseph R. Fauver<sup>1,2</sup>, Barb Andre<sup>1</sup>, Meg Gray<sup>1,2</sup>, William C. Black IV<sup>1,2</sup>, Rebekah C. Kading<sup>1,2</sup>, Gregory D. Ebel<sup>1,2</sup>, Guillermina Kuan<sup>4</sup>, Angel Balmaseda<sup>5</sup>, Thomas Jaenisch<sup>6,7</sup>, Ernesto T. A. Marques<sup>8,9</sup>, Aaron C. Brault<sup>3</sup>, Eva Harris<sup>10</sup>, Brian D. Foy<sup>1,2</sup>, Sandra L. Quackenbush<sup>1</sup>, Rushika Perera<sup>1,2</sup>, Joel Rovnak<sup>1\*</sup>

#### Affiliations:

<sup>1</sup>Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.

<sup>2</sup>Arthropod-borne Infectious Disease Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.

<sup>3</sup>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA.

<sup>4</sup>Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.

<sup>5</sup>Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

<sup>6</sup>Section Clinical Tropical Medicine, Department for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.

<sup>7</sup>German Centre for Infection Research (DZIF), partner site Heidelberg, Germany

<sup>8</sup>Laboratory of Virology and Experimental Therapeutics, Centro de Pesquisas Aggeu Magalhaes, Fundacao Oswaldo Cruz, Recife-PE, Brazil.

<sup>9</sup>Center for Vaccine Research, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.

<sup>10</sup>Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 9472s, USA.

†These authors contributed equally to this work.

\*Correspondence to: joel.rovnak@colostate.edu.




Fig. S1. Zika-specific, RNA-dependent LAMP amplification was confirmed. (A) PCR amplification of 1  $\mu$ l of a 1:500 dilution of the PRVABC59 LAMP product with B3 and F3 LAMP primers to produce a single, predicted 284-bp amplicon. (B) PRVABC59 LAMP product (lane 1) was digested with *AluI* restriction endonuclease to yield predicted 55 and 66-bp fragments (lane 2). Molecular weight standards, 100-bp ladders. (C) RNase A digestion abrogates LAMP signal. Total RNA from PRVABC59-infected cells were treated with RNase A and the RNase heat inactivated prior to PRVABC59 LAMP. RNased and heat-treated positive-control RNA (blue crosses, below threshold), heat-treated positive-control RNA (blue triangles), positive-control RNA (red circles), buffer (black line, below threshold).




Fig. S2. Control samples contain virus RNA. **(A)** RT-PCR amplifications of Zika virus RNA preparations with Zika virus-specific primers yield the predicted 109-bp amplicon from all four Zika virus RNA preparations; lanes 1-5, PRVABC59, MR-766NIID, 41525, P6-740 and buffer control. Position of 100-bp molecular weight marker is indicated. **(B)** RT-PCR amplifications of flavivirus RNA preparations with pan-flavivirus primers yield predicted ~1000-bp amplicons from 8 different viruses; lanes 1-9, Bussuquara, St. Louis encephalitis, Langat, Powassan, Ilheus, West Nile, DENV-2, YFV and buffer control. Position of 1000-bp molecular weight marker is indicated. **(C)** RT-PCR amplification of CHIKV RNA preparation with CHIKV virus-specific primers yield the predicted 112-bp amplicon (lane 1), buffer control (lane 2). Position of 100-bp molecular weight marker is indicated. **(D)** LAMP amplification of DENV-2, WNV, and YFV RNAs with their respective, specific LAMP primers (blue boxes) and amplification PRVABC59 RNA with PRVABC59-specific primers (red circles). DENV-2, WNV, and YFV RNAs were not amplified with PRVABC59-specific primers (blue diamonds, below threshold), and PRVABC59 RNA was not amplified with DENV-, WNV-, or YFV-specific LAMP primers (black circles, below threshold).



B.

B1 (5' BIP)

B2c (3' BIP)

B3

1. KU501215	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	PRVABC59
2. KX369547	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
3. KX280026	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
4. KX253996	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
5. KX212103	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
6. KX197192	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
7. KX185891	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
8. KX117076	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
9. KX087101	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
10. KU963796	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
11. KU955589	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
12. KU940228	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
13. KU940227	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
14. KU940224	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
15. KU937936	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
16. KU926310	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
17. KU926309	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
18. KU866423	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
19. KU853013	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
20. KU853012	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
21. KU820899	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
22. KU758877	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
23. KU729218	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
24. KU729217	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
25. KU707826	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
26. KU509998	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
27. KU365780	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
28. KU365779	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
29. KU365778	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
30. KU365777	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
31. KU321639	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
32. KU312312	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
33. KJ776791	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
34. KX446950	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
35. KX262887	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
36. KX247632	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
37. KX051563	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
38. KU991811	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
39. KU870645	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
40. KU527068	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
41. KU501217	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
42. KU820898	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
43. KU761564	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
44. KU740184	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
45. KX056898	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
46. KU955590	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
47. KX520666	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
48. KX446951	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
49. KX198135	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
50. KU497555	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
51. KU922960	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
52. KU922923	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
53. KU647676	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
54. KX548902	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
55. KX247646	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
56. KU820897	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
57. KX156774	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
58. KU681082	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
59. KU681081	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
60. KF993678	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAAAAG	TA CGAG CGA TGG TTG TTCC	
61. KU955593	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
62. JN860885	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
63. EU545988	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
64. HQ234499	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
65. LC002520	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	P6-740
66. KU963574	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	MR-766
67. KU963573	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
68. HQ234500	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
69. KF268950	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
70. KF268949	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
71. KF268948	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
72. KF383120	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
73. KF383121	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
74. KF383119	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
75. KF383118	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
76. KF383116	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
77. KF383115	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
78. KU955595	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
79. KU955592	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
80. KU955591	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	41525
81. KF383117	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
82. KX198134	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	
83. HQ234501	TCAAAGTCAGACCAGCGTTGCT	AA TTGGACACCCCGTGAGAG	TA CGAG CGA TGG TTG TTCC	

South and Central America and Caribbean

Southeast Asia

Africa

Fig. S3. Alignment of Zika LAMP primer sequences with target sequences in all known Zika virus sequences were carried out. Primer sequences F3, F2 and F1c (**A**) and B1, B2c and B3 (**B**) are presented in 5' to 3' orientation according to position in the virus genome. FIP and BIP primers (Table S1) are fusions of F2 and the inverse complement of F1c and B1 and the inverse complement of B2c, respectively (Fig.1A). BIP and FIP junctions are indicated by connecting lines above the PRVABC59 sequence (KU501215). Blast alignments were based on the entire 284-bp, LAMP amplicon bound by primers F3 and B3 (Fig. 1A). The sequences of the four strains tested, PRVABC59, P7-740, MR-766NIID, and 41525, are indicated as are the geographic regions where strains were isolated: South and Central America and Caribbean, Southeast Asia (including Micronesia), and Africa. Multiples of identical whole virus sequences with different accession numbers were excluded from the alignment.




Fig. S4. Direct detection of Zika virus in mosquitoes was accomplished. LAMP amplification of 15 individual homogenates of infected mosquitoes at 7 days post infection (blue lines), positive control RNA (red circles), buffer control (black line, below threshold).




Fig. S5. Zika-specific LAMP amplification from mosquito homogenates was confirmed. (A) PCR amplification of 1  $\mu$ l of a 1:100 dilution of PRVABC59 LAMP product with B3 and F3 LAMP primers produced the predicted 284-bp amplicon. (B) PRVABC59 LAMP product (lane 1) was digested with *AluI* restriction endonuclease to yield predicted 55 and 66-bp fragments (lane 2). Molecular weight standards, 100-bp ladders.




Fig. S6. Zika LAMP assay is dependent upon RNA. **(A)** RNase A digestion abrogates LAMP signal from mosquitoes. Mosquito homogenates from 2 mock-infected and 2 infected animals were incubated with or without RNase A and heat inactivated prior to PRVABC59 LAMP: infected and RNased (red crosses, below threshold), infected and mock-RNased (red circles), mock-infected and RNased (blue crosses, below threshold), mock-infected and non-RNased homogenate (blue circles, below threshold), buffer control (black line, below threshold). **(B)** DNase I digestion enhances LAMP amplification. An infected mosquito homogenate was incubated with or without DNase I and heat inactivated prior to PRVABC59 LAMP amplification in triplicate: DNase-digested (blue squares), mock-digested (red circles) and buffer control (black line, below threshold).






Fig. S7. A visual LAMP assay was tested using mosquito homogenates. Mock and infected mosquito homogenates were amplified and reactions inspected for turbidity. Tube 1, buffer control; tube 2, mock-infected mosquito homogenate; tube 3, infected mosquito homogenate; tube 4, infected Vero cell RNA.




Fig. S8. Limits of PRVABC59-LAMP detection match RT-PCR. **(A)** PRVABC59-specific LAMP of serial, tenfold dilutions of 10 ng of total RNA. 10 ng (red circles), 1 ng (blue circles), 100 pg (blue triangles), 10 pg (blue squares), 1 pg (blue diamonds), 100 fg (blue crosses), 10 fg (green crosses, below threshold), 1 fg (red crosses, below threshold), buffer control (black line, below threshold). **(B)** Agarose gel electrophoresis of LAMP products in **(A)** and RT-PCR products from the same dilution series produced with Zika-specific PCR primers after reverse transcription (**lower panel**). Predicted amplicon from RT-PCR is 109 bp. Positions of 100-bp molecular weight markers are indicated. Molecular weight standards are 100-bp ladders.




Fig. S9. The LAMP assay detects PRVABC59 virus in human biofluids. (A) LAMP of 2  $\mu$ l of serial tenfold dilutions in water of blood, plasma, urine, saliva and semen containing PRVABC59 virus at  $1 \times 10^6$  PFU/ml. Undiluted (blue circles),  $10^{-1}$  (blue triangles),  $10^{-2}$  (blue squares),  $10^{-3}$  (blue diamonds),  $10^{-4}$  (blue crosses) and  $10^{-5}$  (blue line, no symbol, below threshold). Positive control RNA (red circles) and un-inoculated biofluids (black line, below threshold).

Table S1. Zika LAMP primers

Primer	Sequence (5'-3')	Position (nt)
F3 Asian	AATGAGTGACCTGGCTAAGC	3694-3713
B3 Asian	GGAACAACCATCGCTCGTA	3978-3960
FIP Asian	GCTATCAGCGCCAGATGAGCTTTGCAATTTTGATGGGTGCC	3786-3766 3715-3733
BIP Asian	TCAAAGTCAGACCAGCGTTGCTCTTTCACGGGGTGTCCAATT	3792-3813 3855-3836
F3 African	AATGAGTGACCTGGCCAAGC	3694-3713
B3 African	GGCACGGCCATTGCTCGAA	3978-3960
FIP African	GCTACCAATGCCAAGTGAGCTTTGTGATCCTGATGGGTGCT	3786-3766 3715-3733
BIP African	TTAAAGTCAGACCAGCCTTGCTCTCTCACGGGGTGTCCAATT	3792-3813 3855-3836

Table S2. Plaque titration of split, infected mosquitoes.

mosq #	dilutions (1 <sup>Ex</sup> )				PFU/ml
	-1	-2	-3	-4	
1	TM	TM	TM	53	2.1x10 <sup>6</sup>
2	TM	TM	TM	33	1.3 x10 <sup>6</sup>
3	TM	21	0	0	8.4 x10 <sup>3</sup>
4	TM	TM	TM	46	1.8 x10 <sup>6</sup>
5	TM	TM	TM	61	2.4 x10 <sup>6</sup>
6	TM	TM	TM	85	3.4 x10 <sup>6</sup>
7	TM	TM	TM	45	1.8 x10 <sup>6</sup>
8	TM	TM	TM	47	1.9 x10 <sup>6</sup>
9	TM	TM	TM	33	1.3 x10 <sup>6</sup>
10	TM	TM	TM	58	2.3 x10 <sup>6</sup>

TM = too many to count

Table S3. Plaque titration of midguts (MG), salivary glands (SG), and carcass

Mosquito number	tissue	# of plaques				titer (PFU/ml)	LAMP
		-1	-2	-3	-4		
11	Carcass		TM	TM	11	$8.8 \times 10^5$	-
	SG	TM	TM	100		$8.0 \times 10^5$	+
	MG	2	0	0		160	-
12	Carcass		0	0	0	0	-
	SG	0	0	0		0	-
	MG	0	0	0		0	+
13	Carcass		0	0	0	0	-
	SG	0	0	0		0	+
	MG	0	0	0		0	+
14	Carcass		0	0	0	0	+
	SG	TM	TM	>150		$>1.2 \times 10^6$	+
	MG	9	4	0		$1.96 \times 10^3$	+
15	Carcass		0	0	0	0	-
	SG	0	0	0		0	+
	MG	0	0	0		0	+

Grey = not tested, TM = too many to count

Table S4A. LAMP assay LOD for genome copies

genome copies	# Pos./Total
100000	6/6
10000	6/6
1000	6/6
100	6/6
50	4/6
25	2/6
13	2/6
10	0/6
6	0/6
1	0/6
0	0/6

LOD 111 genome copies (95% CI: 58- 1148)

Table S4B. TaqMan LOD for genome copies

genome copies	# Pos./Total	Mean Cq
100000	4/4	23.61
10000	4/4	26.96
1000	4/4	30.53
100	4/4	34.93
50	4/5	
25	4/5	
10	4/16	37.82
6	1/6	
5	4/18	
3	1/12	
1.3	1/12	
1	1/4	
0.7	0/12	
0.1	0/4	

LOD 53 genome copies (95% CI: 38 – 98)

Table S5A. Plasma 1:1000 LOD	PFU/ml	PFU/ RXN	# pos./Total
	1000000	2	6/6
	100000	.2	6/6
	50000	.1	6/6
	25000	.05	6/6
	12500	.025	3/6
	6000	.012	1/6
	1000	.002	0/6
	0	0	0/6

LOD 0.05 PFU (95% CI: 0.03 - 0.42)

Table S5B. Plasma 1:1000 turbidity LOD	PFU/ml	PFU/ RXN	# pos./Total
	1000000	2	6/6
	100000	.2	6/6
	50000	.1	5/6
	25000	.05	4/6
	12500	.025	3/6
	6000	.012	2/6
	1000	.002	0/6
	0	0	0/6

LOD 0.17 PFU (95% CI: 0.08 - 2.52)

Table S6. Blood 1:1000 LOD

PFU/ml	PFU/RXN	# pos./Total
1000000	2	6/6
100000	0.2	6/6
50000	.1	6/6
25000	.05	6/6
12500	.025	3/6
6000	.012	2/6
500	.001	0/6
0	0	0/6

LOD 0.05 PFU (95% CI: 0.03 - 0.25)

Table S7. Urine 1:1000 LOD	PFU/ml	PFU/RXN	# pos./Total
	1000000	2	6/6
	500000	1	6/6
	250000	0.5	6/6
	125000	0.25	5/6
	60000	0.12	1/6
	10000	0.02	0/6
	0	0	0/6

LOD 0.32 PFU (95% CI: 0.22 - 3.26)

Table S8. Saliva 1:1000 LOD

PFU/ml	PFU/RXN	# pos./Total
1000000	2	6/6
100000	0.2	6/6
50000	0.1	5/6
25000	0.05	2/6
12500	0.025	0/6
6000	0.012	0/6
1000	0.002	0/6
0	0	0/6

LOD 0.13 PFU (95% CI: 0.09 - 0.86)

Table S9. Semen 1:1000 LOD

PFU/ml	PFU/RXN	# pos./Total
1000000	2	5/6
500000	1	2/6
250000	0.5	1/6
125000	0.25	1/6
60000	0.12	0/6
10000	0.02	0/6
0	0	0/6

LOD 5.57 PFU (CI:2.18608.14)



Table S10. Nicaraguan serum and serum RNA samples

Sample #	Cq (rep1)	Cq (rep2)	Cq Mean	Cq Error	RNA qRT-PCR	RNA LAMP	Direct LAMP	qRT-PCR Code
1	33.21	32.6	32.91	0.43	+	+	+	+
2	31.74	31.18	31.46	0.4	+	+	+	+
3	31.67	31.39	31.53	0.2	+	+	+	+
4	27.05	27.08	27.07	0.02	+	+	+	+
5	35	35.52	35.26	0.37	+	+	+	+
6	-	-	-	-	-	-	+	-
7	-	-	-	-	-	-	-	-
8	-	-	-	-	-	-	+	-
9	-	-	-	-	-	-	-	-
10	37.67	-	37.67	0	+	+	+	+
11	31.71	31.63	31.67	0.06	+	+	+	+
12	34.23	34.65	34.44	0.3	+	+	+	+
13	30.05	30.12	30.09	0.05	+	+	+	+
14	34.62	35.49	35.06	0.62	+	+	+	+
15	33.42	33.63	33.53	0.15	+	+	+	+
16	-	-	-	-	-	-	-	-
17	-	-	-	-	-	-	-	-
18	-	-	-	-	-	-	-	-
19	-	-	-	-	-	+	+	-
20	31.53	31.53	31.53	0	+	+	+	+
21	35.26	35.03	35.15	0.16	+	+	+	+
22	37.93	-	37.93	0	+	+	+	+
23	34.78	34.15	34.47	0.45	+	+	-	+
24	31.28	31.56	31.42	0.2	+	+	-	+
25	-	-	-	-	-	-	-	-
26	-	-	-	-	-	-	-	-
27	-	-	-	-	-	-	+	-
28	-	-	-	-	-	-	-	-
29	25.79	25.79	25.79	0	+	+	+	+
30	37.31	37.76	37.54	0.32	+	-	+	+
31	-	-	-	-	-	+	+	+
32	25.92	25.92	25.92	0	+	+	+	+
Total Positive					19	20	22	20

Table S11. Brazilian plasma and RNA samples

Sample #	qRT-PCR		Serology		Combined qRT-PCR Serology	LAMP plasma	LAMP RNA	LAMP Plasma and RNA
	Ct	Result	IgM	Result				
1	31.70	+	5.2	+	+	+	+	+
2	30.43	+	n.d.	n.d.	+	-	n.d.	-
3	32.41	+	n.d.	n.d.	+	+	+	+
4	35.72	+	n.d.	n.d.	+	+	+	+
5	35.17	+	7.1	+	+	+	-	+
6	34.74	+	15.5	+	+	+	+	+
7	34.17	+	14.6	+	+	+	+	+
8	34.21	+	n.d.	n.d.	+	-	+	+
9	32.96	+	8.0	+	+	+	n.d.	+
10	-	-	1.5	-	-	+	+	+
11	-	-	11.3	+	+	-	n.d.	-
12	-	-	19.2	+	+	+	n.d.	+
13	-	-	9.9	+	+	+	n.d.	+
14	35.66	+	14.4	+	+	-	-	-
15	35.13	+	n.d.	n.d.	+	+	+	+
16	35.94	+	17.6	+	+	+	-	+
17	36.97	+	n.d.	n.d.	+	-	-	-
18	-	-	5.9	+	+	+	n.d.	+
19	-	-	14.7	+	+	+	n.d.	+
20	-	-	1.9	-	-	-	n.d.	-
21	-	-	1.0	-	-	+	n.d.	+
22	31.14	+	7.6	+	+	+	+	+
23	33.39	+	13.6	+	+	+	+	+
24	28.36	+	n.d.	n.d.	+	+	+	+
25	34.87	+	14.3	+	+	-	+	+
26	36.13	+	n.d.	n.d.	+	+	-	+
27	36.09	+	16.7	+	+	+	+	+
28	-	-	0.9	-	-	+	n.d.	+
29	-	-	n.d.	n.d.	-	-	n.d.	-
30	-	-	1.0	-	-	+	n.d.	+
31	24.48	+	n.d.	n.d.	+	+	+	+
32	-	-	1.8	-	-	+	n.d.	+
33	-	-	1.3	-	-	-	n.d.	-
34	-	-	0.9	-	-	+	n.d.	+
35	33.71	+	5.2	+	+	-	+	+
36	30.73	+	10.7	+	+	-	-	-
37	36.73	+	n.d.	n.d.	+	-	+	+
38	34.42	+	n.d.	n.d.	+	-	+	+
39	-	-	1.8	-	-	+	+	+
40	-	-	2.9	+	+	+	n.d.	+
41	-	-	0.8	-	-	+	n.d.	+
42	-	-	1.1	-	-	-	n.d.	-
43	-	-	1.9	-	-	+	n.d.	+
44	-	-	1.0	-	-	+	-	+
45	-	-	0.9	-	-	-	n.d.	-
46	-	-	0.9	-	-	-	n.d.	-
47	-	-	1	-	-	+	n.d.	+
48	34.18	+	n.d.	n.d.	+	+	-	+
49	-	-	1.1	-	-	+	n.d.	+
Total +	25		19/36		31	33	18/26	38